Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00023361 · ClinicalTrials.gov registry record · NA
TBTC Study 23: Treatment of HIV-Related Tuberculosis Using a Rifabutin-Based Regimen
A NA study of HIV Infections and Tuberculosis, sponsored by Centers for Disease Control and Prevention.
- Completed
- Registry status
- NA
- Development phase
- 215
- Enrollment target
- 20
- Study locations
NCT00023361 is a NA study of HIV Infections and Tuberculosis that has completed, run by Centers for Disease Control and Prevention. The registered enrollment target is 215 participants, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (52% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT00023361, a NA study of HIV Infections and Tuberculosis, has completed, sponsored by Centers for Disease Control and Prevention.
- COMPLETED
- Registry status
- NA
- Development phase
- 215 participants
- Enrollment target
- 20
- Study locations
Study Summary
Primary objective: To determine the rate of confirmed treatment failure and relapse with an intermittent rifabutin-based regimen for the treatment of isoniazid and rifamycin-susceptible HIV-related tuberculosis (TB).
Conditions Studied
Interventions
- DRUG Rifabutin
Study Locations (20)
New York
- New York University School of Medicine - New York
- Columbia University/Presbyterian Medical Center - New York
- Harlem Hospital Center - New York
Texas
- University of North Texas Health Science Center - Fort Worth
- Thomas Street Clinic - Houston
- Audi L. Murphy VA Hospital - San Antonio
California
- LA County/USC Medical Center - Los Angeles
- University of California, San Francisco - San Francisco
Illinois
- Chicago VA Medical Center (Lakeside) - Chicago
- Hines VA Medical Center - Hines
North Carolina
- Carolinas Medical Center - Charlotte
- Duke University Medical Center - Durham
Arkansas
- Central Arkansas Veterans Health System - Little Rock
Colorado
- Denver Department of Public Health and Hospitals - Denver
District of Columbia
- Washington, D.C. VAMC - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 215 participants |
| Start Date | 1999-02 |
| Est. Completion | 2003-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00023361
The ClinicalTrials.gov registry entry for NCT00023361 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 215 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (52% lower). The listed sponsor is Centers for Disease Control and Prevention, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Rifabutin is the first listed.
NCT00023361 reports 20 study locations spanning 13 distinct geographic areas - top geographies include New York, Texas, California.
Frequently Asked Questions
What is clinical trial NCT00023361 about?
NCT00023361 is a clinical study titled "TBTC Study 23: Treatment of HIV-Related Tuberculosis Using a Rifabutin-Based Regimen". Primary objective: To determine the rate of confirmed treatment failure and relapse with an intermittent rifabutin-based regimen for the treatment of isoniazid and rifamycin-susceptible HIV-related tuberculosis (TB).
What is the current status of trial NCT00023361?
This trial is currently completed. It is a NA study. The enrollment target is 215 participants. The study started on 1999-02. Estimated completion is 2003-02.
What conditions does trial NCT00023361 study?
This clinical trial studies the following conditions: HIV Infections, Tuberculosis.
What interventions are being tested in trial NCT00023361?
The interventions under investigation include: Rifabutin (DRUG).
Who is sponsoring clinical trial NCT00023361?
This trial is sponsored by Centers for Disease Control and Prevention, which has 139 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00023361 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, District of Columbia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
RECRUITING · NA
-
Community-based Education, Navigation, and Support Intervention for Military Veterans
RECRUITING · NA
-
WiseApp for Spanish Speakers Living With HIV
RECRUITING · NA
-
Comprehensive HIV and Harm Prevention Via Telehealth
RECRUITING · NA
-
Substance Checking Outreach and Pre-Exposure Prophylaxis (PrEP) Engagement Study
RECRUITING · NA
-
Food as Medicine for HIV and Diabetes
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.